Research and development, as well as manufacturing, of pharmaceutical intermediates and research reagents.
We specialize in the production of heterocyclic compounds, including kinorinone (carboschiral) derivatives, indole, and azepinone-related compounds.
Carbostyril, 2(1H)-Quinolinone derivatives 3,4-Dihydro-1H-quinolin-2-one derivatives Indole derivatives 1, 3, 4, 5-Tetrahydro-benzo[b]azepin-2-one derivatives Aryl piperazine Heterocyclic compound
Inquire About This Product
basic information
Friedel-Crafts Reaction: approximately 10~120kg/batch Amidation: approximately 15~300kg/batch Acetylation: approximately 5~300kg/batch Alkylation: approximately 10~200kg/batch Sulfonamidation: approximately 15~60kg/batch Hydrogen Reduction: approximately 5~70kg/batch Halogenation: approximately 5~170kg/batch Nitration: approximately 1~10kg/batch Chloroquinoline: approximately 10~50kg/batch Piperazine Ring Formation: approximately 2~100kg/batch
Price range
Delivery Time
Applications/Examples of results
Alkylation reactions by Friedel-Crafts Amidation using Schotten-Baumann reaction, etc. Acetylation of aromatic hydroxyl groups Alkylation reactions of aromatic amines and hydroxyl groups Tosylation reactions of aromatic amines Hydrogenation reactions using Pd/C (under one atmosphere) Chlorination (SOCl2) and bromination (NBS) reactions Aromatic nitration reactions using flow devices Chloroketone reactions using chlorinating agents Synthesis of aryl piperazines *For more details, please feel free to contact us.*
catalog（2）
Download All Catalogs
Company information
Our company was established in 1919 with the corporate philosophy of "contributing to society through chemistry that connects the flask to the plant." We have repeatedly engaged in the research and development of pharmaceutical intermediates, built our unique synthesis technology, and provided high-quality, custom-made products to meet our customers' needs as a research and development-oriented company. Moving forward, we will continue to base our business on fine chemicals, accelerate our efforts in the research and development of pharmaceutical intermediates, and promote the research and development of distinctive organic compounds by introducing new technologies.